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PCSK9 INHIBITORS AS A THERAPY FOR HYPERCHOLESTEROLEMIA 
MAIA NOFAL 
ABSTRACT 
 The recent discovery of proprotein convertase subtilisin/kexin type 9 as a protein 
that increases LDL-cholesterol has lead researchers to investigate it as a target for 
cholesterol-lowering medication. New options for cholesterol-lowering therapies are of 
particular importance for individuals, such as those with familial hypercholesterolemia 
and statin intolerance, who are unable to achieve recommended values through other 
means. Currently, two monoclonal antibodies inhibiting PCSK9 are approved for use; 
these monoclonal antibodies work well in conjunction with other medications for 
hypercholesterolemia, such as statins or ezetimibe, and are equivalent in efficacy with 
high dose statins. Investigation of PCSK9 inhibitors through siRNA may provide 
additional mechanisms for lowering cholesterol in the future.  
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INTRODUCTION 
 73.5 million adult Americans, or 31.7% of the US population, have high low-
density lipoprotein (LDL) cholesterol; these individuals have approximately double the 
risk of developing cardiovascular disease as compared with individuals with normal 
LDL-cholesterol (“High Cholesterol Facts | cdc.gov,” n.d.). Since the creation of 
lovastatin, the first commercial statin, in 1982, statins have been the drug of choice for 
many patients with high LDL-cholesterol (Endo, 2010). While statins are generally well 
tolerated and have minimal side effects, not everyone taking statins is able to achieve the 
necessary reduction in LDL-cholesterol (Endo, 2010; Banach et al., 2015). Due to the 
recent discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, 
new, promising medication may be available to help lower LDL-cholesterol apart from 
statins. 
 Two groups of individuals generally struggle to reduce their LDL-cholesterol to 
recommended levels: individuals with statin intolerance and those who suffer from the 
genetic disorder, familial hypercholesterolemia. Statin intolerance is the inability to 
tolerate the dose necessary to sufficiently decrease plasma LDL-cholesterol to reduce 
cardiovascular risk (Banach et al., 2015). Familial hypercholesterolemia is a genetic 
disorder that results from a number of different mutations resulting in the inability to 
regulate plasma cholesterol appropriately.  
 Currently, two PSCK9 inhibitors have been approved as medication for 
hypercholesterolemia. The goal of this literature review will be to delineate key 
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information regarding PSCK9 inhibitors’ cholesterol-lowering properties and analyze 
their efficacy and the need for further investigation. 
  
LDL-Cholesterol Function and Recommendations 
 LDL-cholesterol is known colloquially as the “bad” cholesterol. High plasma 
LDL-cholesterol is predictor of cardiovascular disease and shows a positive correlation 
with coronary artery disease (Tibolla et al., 2011). LDL-cholesterol is in many ways 
modifiable through lifestyle choices but variation is thought to be 50% genetic (Kotowski 
et al., 2006). Additionally, when LDL-cholesterol is lowered through lipid-lowering 
drugs, risk of cardiovascular disease lowers as well (Tibolla et al., 2011). LDL is 
responsible for transporting 60-70% of plasma cholesterol (Tibolla et al., 2011). It is 
derived from very low-density lipoprotein (VLDL) and contains Apolipoprotein B-100 
(ApoB-100), which is involved in mediating LDL-cholesterol’s interaction with the LDL-
receptor on liver and extra-hepatic cells (Mahley, Innerarity, Rall, & Weisgraber, 1984). 
LDL-cholesterol is removed from the circulation when LDL-cholesterol binds to the 
LDL-receptor in the liver and taken up through endocytosis in clathrin-coated vesicles 
(Farnier, 2014) The details of LDL-cholesterol regulations can been seen in Figure 1.  
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Figure 1. LDL-Cholesterol regulation in hepatic cells. From Champe et al., 2015. 	
To reduce risk of cardiovascular disease, LDL-cholesterol levels should remain 
below 100mg/dL, according to United States recommendation (“Cholesterol Fact 
Sheet|Data & Statistics|DHDSP|CDC,” n.d.). Recommendations for individuals with 
familial hypercholesterolemia differ slightly; recommended values are listed in Table 1. 
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Table 1. Recommended LDL-cholesterol targets for individuals with familial 
hypercholesterolemia. 
Children 135 mg/dL 
Adults 100 mg/dL 
Adults with cardiovascular disease or 
diabetes 
70 mg/dL 
(“Familial Hypercholesterolemia Treatment & Management,” 2015) 
 
Cholesterol levels are managed through both medications, such as statins, and through 
lifestyle adjustments. Lifestyle modification include regular exercise, diet limiting 
saturated fats, trans fats, and dietary cholesterol, and weight maintenance at a health body 
mass index (BMI) (by European Atherosclerosis Society (2013). 
 
Genetics and Treatment Challenges of Familial Hypercholesterolemia 	 Familial hypercholesterolemia is one of the most common genetic disorders in the 
world, affecting 12 million people worldwide (Raal et al., 2012). Familial 
hypercholesterolemia results in dyslipidemia, including plasma LDL-cholesterol levels 
above 200mg/dL, tendon xanthomas, and premature morbidity and mortality from 
cardiovascular disease (Raal et al., 2012; Timms et al., 2004).  Symptoms begin to 
manifest in the fourth decade of life in men and the fifth decade of life in women, leading 
to a risk of cardiovascular death before the age of fifty in men and sixty in women 
(Sjouke et al., 2011; Raal et al., 2012). This early onset of cardiovascular disease can be 
further exacerbated by modifiable risk factors, such as smoking, hypertension, and 
diabetes (Sjouke et al., 2011).  
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 Familial hypercholesterolemia undergoes autosomal dominant inheritance (Sjouke 
et al., 2011). Most types of familial hypercholesterolemia result from a loss of function 
mutation to the LDL-receptor (Raal et al., 2012). Amongst patients with loss of function 
mutations to the LDL-receptor, upwards of 1,600 different mutations have been found 
(Raal et al., 2012). Most of these people are heterozygotes, who can be found with a 
frequency of 1 in 500 in the general population, although they occur more commonly in 
certain populations that have undergone the gene founder effect, such as French 
Canadians and Afrikaner South Africans (Tibolla et al., 2011; Raal et al., 2012). 
Homozygotes are uncommon as consanguineous marriage between two heterozygotes is 
unlikely (Raal et al., 2012). However, they can occasionally be found in the population at 
a rate of one in one million (Tibolla et al., 2011). Familial hypercholesterolemia 
undergoes a gene dosage response, with heterozygotes having twice the plasma LDL-
cholesterol as compared with homozygotes, who can have up to four times the normal 
levels of plasma LDL-cholesterol (Soutar & Naoumova, 2007). 
 While most people with familial hypercholesterolemia have loss of function 
mutations to the LDL-receptor, two other types of mutations have also been found. Most 
notably, the mutations in ApoB and PCSK9, both of which are also autosomal dominant 
(Sjouke et al., 2011).  
 Patients with familial hypercholesterolemia do not achieve the recommended 
necessary plasma LDL-cholesterol levels, even while on statins, bile acid sequestering 
agents, and ezetimibe, a cholesterol-lowering drug that acts on the small intestine (Raal et 
al., 2012). Typically, these medications are only successful in lowering LDL-cholesterol 
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between 50-60% (Raal et al., 2012). Furthermore, it is difficult to tailor a single drug 
regiment to all patients with familial hypercholesterolemia, as like normal patients they 
experience variation in how they react to these drugs (Soutar & Naoumova, 2007). As a 
result of the difficulties, treating familial hypercholesterolemia has presented a significant 
challenge over the last few decades.  
 
Statin Function and Intolerance 
 Statins, known scientifically as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase inhibitors, were the best drug known to lower plasma cholesterol levels at 
the time of their discovery, effectively slowing the progression of atherosclerosis while 
producing very few side effects (Stancu & Sima, 2001). In some cases, patients 
undergoing treatment with statins even showed regression of atherosclerotic plaques 
through angiography (Stancu & Sima, 2001). Statins function by inhibiting HMG-CoA 
reductase and prevent the enzyme from completing the synthesis of endogenous 
cholesterol (Stancu & Sima, 2001) The function of HMG-CoA is graphically represented 
in Figure 2. Competing with HMG-CoA, statins bind HMG-CoA reductase reversibly, 
but change the conformation of the active site, preventing future binding by HMG-CoA 
(Stancu & Sima, 2001). 
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Figure 2. HMG-CoA Reductase regulation of SREBP. From Champe et al., 2005 
 
Apart from their inhibition of HMG-CoA reductase, statins have numerous other effects. 
In particular, statins are able to increase the uptake and degradation of LDL-cholesterol 
(Stancu & Sima, 2001). By reducing the intracellular cholesterol through inhibiting 
HMG-CoA reductase, statins induce a response from sterol response element binding 
proteins (SREBPs), which travel to the nucleus and increase gene expression for the 
LDL-receptor (Figure 2); an increase in the number of LDL-receptors present in the 
hepatocyte cell membrane allows the liver to remove more LDL-cholesterol (Stancu & 
Sima). This is very effective because the liver is responsible for removing about 50% of 
the LDL-cholesterol from the blood (Stancu & Sima, 2001). This mechanism of 
increasing LDL-receptors via SREBP induction remains relevant because SREBP is also 
involved in increasing expression of PCSK9, a protein that ultimately increases plasma 
LDL-cholesterol levels, competing with the effects of statins (Tibolla et al., 2011). 
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 Statins have been successful over the last several decades in lower cholesterol in 
most patients. The lowest dose of a daily statin can lower a patient’s LDL-cholesterol 
between 20-40% (Mampuya et al., 2013). Doubling the dose after baseline can further 
lower plasma LDL-cholesterol an additional 6-7% (Mampuya et al., 2013).  
 While statins are generally well tolerated, they can occasionally cause side 
effects, sometimes to the point where patients are deemed “statin intolerant,” about 10-
15% of hypercholesterolemia patients (Banach et al., 2015). The most common side 
effects are often muscle related; these symptoms have been called statin-associated 
myalgia/myopathy (Banach et al., 2015). Nonetheless, other symptoms have been noted, 
including nausea, headache, and arthritis (Banach et al., 2015). While some individuals 
with statin intolerance are able to tolerate intermittent doses of statins as opposed to daily 
dosing, this may not be effective as the full dose (Mampuya et al., 2013). Instead, 
individuals with statin intolerance are treated with ezetimibe, bile sequestration agents, or 
lifestyle modification, none of which are able to offer the same efficacy as statins in 
lowering cholesterol (Vandenberg & Robinson, 2010).  These difficulties with statin 
intolerance create an excellent opportunity for alternate treatment options, such as 
PCSK9 inhibitors. 
 
PCSK9 – Discovery and Function 
 PCSK9, the ninth member of the proprotein convertase family, increases LDL-
cholesterol by decreasing the number of LDL-receptors on the hepatocyte membrane 
(Gencer et al., 2015). PCSK9 was first discovered in 2003 when gain of function 
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mutations in PCSK9 were noted in several families with familial hypercholesterolemia 
that had no mutations to ApoB-100 or the LDL-receptor (Farnier, 2014). Other mutations 
in PCSK9 have been observed since, resulting in a range of hypercholesterolemia, but the 
frequency of these mutations remain low amongst people with hypercholesterolemia 
(Farnier, 2014). Since the discovery of the PCSK9 gene, loss of function mutations and 
polymorphisms reducing PCSK9 function have been found in a number of people, all 
resulting in decreased plasma LDL-cholesterol and a reduced lifetime risk of 
cardiovascular disease (Farnier, 2014; Gencer et al., 2015). A meta-analysis looking at a 
particular loss of function mutation called R46L showed a 12% reduction in LDL-
cholesterol and a 28% reduction in cardiovascular disease, a larger drop in cardiovascular 
disease than might be expected with a similar reduction in LDL-cholesterol using statins 
(Farnier, 2014).  
 The gene for PCSK9 is found on chromosome 1 and is 12 exons long; it results in 
a 692 amino acid glycoprotein expressed in the liver, intestine, and kidneys (Tibolla et 
al., 2011; Farnier 2014). PCSK9 is synthesized as a 75 kDa soluble zymogen called 
proPCSK9, which undergoes autocatalytic cleavage in the endoplasmic reticulum at 
position 152 (Tibolla et al., 2011). This results in a 14 kDa propetide and a 60 kDa 
mature protein (Tibolla et al., 2011). This autocatalytic cleavage is required for 
maturation and secretion (Farnier, 2014). 
 The catalytic domain of PCSK9 mature protein is made up of aspargines, 
histidines, and serines (Timms et al., 2004). After cleavage, the propeptide C-terminus 
hydrogen bonds with a particular histidine, His266, on the active site of the mature 
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protein, preventing the mature protein from becoming enzymatically active (Tibolla et al., 
2011). The 75 kDa PCSK9/proprotein complex then exits the cell through the secretory 
pathway (Tibolla et al., 2011). After release of the PCSK9/proprotein complex, a protein 
called furin can cleave the PCSK9/proprotein compext at Arg218, which is one method 
that PCSK9 concentrations are reduced (Tibolla et al., 2011; Farnier 2014). 
 PCSK9 functions primarily as a secreted factor that interacts with the LDL-
receptor and targets it for degradation in the lysosome rather than allowing it to recycle 
back to the cell membrane (Farnier, 2014; Au et al., 2015). Secreted PCSK9 binds to the 
LDL-receptor at a one-to-one ratio via the first epidermal growth factor homology 
domain (EGF-A) on the extracellular portion of the LDL-receptor (Tibolla et al., 2011). 
The specificity of this binding to EDF-A is due to a highly conserved sequence, Cys317, 
Leu318, Cys319 (Tibolla et al., 2011).   
 After binding to the LDL-receptor, PCSK9 is internalized into the cell as a 
complex with the LDL-receptor (Tibolla et al., 2011). As the pH drops inside the cell, the 
C-terminus of PCSK9 binds the ligand-binding domain on the LDL-receptor, 
strengthening their interaction and preventing the dissociation of the LDL-receptor and 
its subsequent recycling (Tibolla et al., 2011). Instead, the complex is directed to the 
lysosome where the LDL-receptor is degraded (Tibolla et al., 2011). The function of 
PCSK9 can be seen in Figure 3.  
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Figure 3. PCSK9 secretion and function. From Tibolla et al., 2011. 
 
The effects of PCSK9 on the LDL-receptor pathway can be seen in Figure 4. While the 
lysosomal pathway is the primary pathway of PCSK9-mediated LDL-receptor 
degradation in hepatocytes, some evidence based on experiments overexpressing PCSK9 
via adenovirus in hepatocytes suggests LDL-receptors in the post-endoplasmic reticulum 
compartments may also be degraded through a PCSK9 mediated pathway (Maxwell et 
al., 2005). 
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(Farnier, 2014) 
 
Figure 4. A: LDL-receptor function; B: Effects of PCSK9 on LDL-receptor function 
  
PCSK9 seems to exhibit a tissue-specific effect on the LDL-receptor; 
overexpression of PCSK9 results in a decrease in the number of LDL-receptors present 
on the liver, but not in other organs such as the adrenal gland and brain (Tibolla et al., 
2011). This tissue-specificity is thought to be related to the presence of Annexin A2 on 
the cell surface, which can bind the C-terminus of circulating PCSK9 and inhibit its 
function (Tibolla et al., 2011). Annexin A2 is notably less prevalent in the liver than in 
the rest of the body (Tibolla et al., 2011). 
 
PCSK9 Gene Expression and Coordination with Statins 
 Gene expression of PCSK9 is primarily dependent on intracellular sterol content 
(Tibolla et al., 2011). The promoter region of the PCSK9 gene includes two sterol 
response elements, which are involved in the sterol-dependent gene regulation; the 
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activation of the gene is mediated by sterol response element binding protein 2 
(SREBP2), which translocates to the nucleus for gene transcription (Tibolla et al., 2011). 
As a result of this regulation through SREBP2, PCSK9 gene expression is coordinated 
with HMG-CoA synthase and HMG-CoA reductase, which are involved in conversion of 
HMG-CoA to mevalonate and subsequent synthesis of cholesterol; additionally, SREBP2 
is also involved in the synthesis of the LDL-receptor (Tibolla et al., 2011). Gene 
expression is also thought to be suppressed by glucagon and bile acids and up regulated 
by inflammation (Tibolla et al., 2011).  
 Because of the coordinated synthesis of the LDL-receptor and PCSK9 via 
SREBP2, pharmacological blockage of cholesterol synthesis and up-regulation of the 
LDL-receptor both result in an increase in PCSK9 gene expression, which in return 
increases plasma LDL-cholesterol by reducing LDL-receptor recycling (Tibolla et al., 
2011). While current day statins are effective for many patients, their maximum potency 
is often not enough for high-risk patients due to the competing effects of PCSK9 (Norata 
et al., 2013).  Statins in particular create an increase in PCSK9 gene expression in a dose-
dependent manner (Table 2) (Dubuc et al., 2004).  
 
Table 2. Effect of atorvastatin dosage on LDL-cholesterol and circulating PCSK9 
 
Dosage Change in plasma LDL-
cholesterol 
Change in circulating 
PCSK9 
10 mg atorvastatin 32% decrease No change 
40 mg atorvastatin 42% decrease 34% increase 
(Tibolla et al., 2011) 
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The data from Table 2 implies that with further reduction in LDL-cholesterol parallels an 
increase in PCSK9 (Tibolla et al., 2011). This suggests that at high doses of statins, 
PCSK9 inhibition could improve the efficacy of statins (Tibolla et al., 2011). The 
mechanism by which PCSK9 inhibitors can be coordinated with statins to further reduce 
LDL-cholesterol is shown in Figure 5. 
 
 
Figure 5. Effects of statins and monoclonal antibodies against PCSK9 on LDL-
cholesterol. From Farnier, 2016. 
 
PCSK9 also appears to interfere with other non-statin treatments of 
hypercholesterolemia, although the mechanisms are not fully understood. Fibrates, such 
as fenofibrate, induce PCSK9 expression in most studies, although the evidence of this 
remains somewhat unclear (Tibolla et al., 2011). This phenomenon could explain why 
adding fenofribrate to cholesterol therapy does not result in the expected drop in 
cholesterol (Tibolla et al., 2011). Ezetimibe, a cholesterol drug that acts on the small 
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intestine, does not appear to affect PCSK9 levels in humans normally, but in patients with 
hypercholesterolemia, higher levels of PCSK9 have been noted when the drug is taken in 
combination with statins as compared with PCSK9 levels in individuals taking statins 
only (Tibolla et al., 2011).  
 
Other Functions of PCSK9 
 While the best-known function of PCSK9 is its effect on the LDL-receptor, it is 
thought to have a number of other metabolic functions. PCSK9 is thought to be involved 
in triglyceride metabolism and accumulation of triglycerides in visceral adipose tissue 
(Farnier, 2014). Furthermore, it may have a role in glucose metabolism, liver 
regeneration, and hepatitis C susceptibility (Farnier, 2014). While these other possible 
function of PCSK9 suggest that lower levels of the protein could lead to problematic side 
effects, patients with loss-of-function mutations resulting in no detectable circulating 
PCSK9 have normal brain, liver, and kidney function while maintaining plasma LDL 
levels as low as 14 mg/dL (Farnier, 2014).  
 PCSK9 inhibition is also thought to have medically beneficial effects on levels of 
lipoprotein a (Lp(a)), an LDL-like protein that also contains an ApoB-100 molecule  
(Tada et al., 2015). Lp(a) is synthesized the liver and has been shown to have a causal 
relationship to coronary artery disease through randomized controlled trials (Tada et al., 
2015; Clark et al., 2009). Lp(a) is higher in patients with familial hypercholesterolemia 
which suggests that it is catabolized along with the LDL-receptor (Tada et al., 2015). 
However, this mechanism of reducing Lp(a) is thrown into question as statins are unable 
	16 
to reduce its concentration (Khera et al., 2013). PCSK9 inhibitors appear able to lower 
Lp(a) as much as 30% although the mechanism for how this occurs remains unclear 
(Tada et al., 2013). 
 
Current Therapeutic Strategies for PCSK9 Inhibition 
 Since the discovery of PSCK9, inhibition has been considered a new target area 
for cholesterol-lowering medication. Three therapeutic strategies have been considered 
for inhibiting PCSK9. The first is the creation of monoclonal antibodies or small peptides 
that inhibit PCSK9 from binding the LDL-receptor (Farnier, 2014). Another strategy is to 
make molecules that interfere with PCSK9 maturation and autocatalytic cleavage, 
preventing a function molecule from being secreted (Tibolla et al., 2011). Lastly, gene 
silencing offers a possible strategy through modified antisense oligonucleotides and short 
interfering RNA (siRNA) (Tibolla et al., 2011).  
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PUBLISHED STUDIES  
 
 PCSK9 inhibitors have been tested in animal experiments and clinical trials on 
patients with hypercholesterolemia as a medication for lowering plasma LDL-cholesterol. 
The following published studies are representative of a number of experiments conducted 
using PCSK9 inhibitors and will shed light on the efficacy of PCSK9 in reducing LDL-
cholesterol levels in patients with hypercholesterolemia. 
 
Inhibiting PCSK9 Gene Expression in Animal Models 
  Animal models have been used to preliminarily test methods of inhibiting PCSK9 
gene expression. This has been done using siRNA or antisense oligonucleotide inhibitors 
as described in the following studies. These methods have been tested on mice and rats as 
well as monkeys to best explore the effects these drugs could have on humans. 
 In two studies, siRNA’s have been used to block the expression of PCSK9 while 
packaged in a lipidoid nanoparticle and delivered intravenously to rodents (Frank-
Kamenetsky et al., 2008; Ason et al., 2011). The first siRNA study considered the effects 
of PCSK9 on rodents and monkeys with different propensities for high cholesterol, 
without combining the treatment with any other known cholesterol medication.  
 First tested in normal mice, 5 mg/kg of the siRNA was shown to decrease the 
PCSK9 response between 60 and 70% along with a 30% decrease in total plasma 
cholesterol (Frank-Kamenetsky et al., 2008). The drop in plasma cholesterol was similar 
to the levels present in mice with one deficient PCSK9 allele, suggesting that a 
significant portion of PCSK9 activity was inhibited (Frank-Kamenetsky et al., 2008). The 
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response of a dose of 5 mg/kg of the siRNA lasted approximately 20 days, with larger 
doses persisting even longer with further decreases in PCSK9 transcription (Frank-
Kamenetsky et al., 2008).  
 Next, this same siRNA was tested on rats that were found to have high resistance 
to large doses of statins (Frank-Kamenetsky et al., 2008). These rats were given 
incrementally increasing doses of the siRNA between 1 mg/kg and 5 mg/kg (Frank-
Kamenetsky et al., 2008). This resulted in a dose dependent reduction in total cholesterol, 
with the highest dose of 5 mg/kg resulting in a 50-60% drop in total cholesterol lasting 
for 10 days followed by a gradual increase in total cholesterol over the subsequent 3 
weeks (Frank-Kamenetsky et al., 2008).  
 To test the efficacy of the siRNA on the human PCSK9 gene, transgenic mice 
were engineered to express human PCSK9 cDNA in the Apolipoprotein E promoter 
region (Frank-Kamenetsky et al., 2008). These mice were given a single 5 mg/kg dose of 
the siRNA; results indicated that PCSK9 transcripts were reduced 70% with a subsequent 
decrease in circulating human PCSK9 by 500-fold (Frank-Kamenetsky et al., 2008).  
 Finally, to test the efficacy of this siRNA in an animal more similar to humans, 
cynomolgus monkeys were selected for the final test of this siRNA (Frank-Kamenetsky 
et al., 2008). Monkeys were given either 1 mg/kg or 5 mg/kg of the siRNA (Frank-
Kamenetsky et al., 2008). The 1 mg/kg dose was found not to be significant enough to 
lower LDL-cholesterol; the 5 mg/kg dose, however, lowered LDL-cholesterol after 3 
days an average of 56% (Frank-Kamenetsky et al., 2008). The highest reduction in LDL-
cholesterol was 70% in one of the monkeys (Frank-Kamenetsky et al., 2008).  
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 In a different study, siRNA was used in conjunction with other cholesterol drugs 
such as ezetimibe and statins (Ason et al., 2011). Here the siRNA was also delivered in a 
lipidoid nanoparticle intravenously (Ason et al., 2011). However, in this experiment, all 
tests were done on mice hemizygous for the LDL-receptor that overexpress human 
cholesteryl ester transferase protein (Ason et al., 2011). Unlike humans, mice typically 
have very low levels of plasma LDL-cholesterol; these two mutations cause an increase 
in LDL-cholesterol, which allow these mice to act as a better model for humans (Ason et 
al., 2011). These mice were fed a low-fat Western diet (Ason et al., 2011).  
 To look at the effects of siRNA on mice taking ezetimibe, the mice were given 10 
mg/kg of ezetimibe per day for 7 days (Ason et al., 2011). Some of the mice were also 
administered 6mg/kg of the siRNA on starting on day 4 and continuing every day for the 
remaining 3 days of the experiment (Ason et al., 2011). Table 3 below shows the change 
in PCSK9 liver mRNA, and serum PCSK9 (Ason et al., 2011). 
 
Table 3. Effects of ezetimibe on PCSK9 with and without PCSK9-inhibiting siRNA 
 
Treatment Change in liver 
PCSK9 mRNA 
at day 3 
Change in 
liver PCSK9 
mRNA at day 
7 
Change in 
serum 
PCSK9 at 
day 3 
Change in 
serum PCSK9 
at day 7 
Ezetimibe (10 
mg/kg) only 
for 7 days 
N/A Increased 2-
fold compared 
to baseline 
N/A Increased 3-
fold compared 
to baseline 
Ezetimibe (10 
mg/kg) for 7 
days, with 
siRNA (6 
mg/kg) added 
at day 4 
Increased 2-fold 
compared to 
baseline 
Reduced 4-fold 
compared to 
baseline 
Increased 2-
fold compared 
to baseline 
Reduced 4-fold 
compared to 
baseline 
(Ason et al., 2011). 
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The data from Table 3 shows that while ezetimibe has significant effects on the levels of 
PCSK9 being transcribed and released into the circulation, the addition of the siRNA 
blocks expression of PCSK9 to an extent that not only reverses the effects of ezetimibe 
but further reduces PCSK9 expression below baseline (Ason et al., 2011). Additionally, 
the non-high density lipoprotein (HDL)-cholesterol, which was used as an approximation 
of LDL-cholesterol, dropped 50% in the mice treated with ezetimibe and siRNA as 
compared with 36% in the mice only treated with ezetimibe (Ason et al., 2011). The mice 
from this experiment had normal liver enzymes and mild inflammation that was not 
severe enough to indicate issues with liver function (Ason et al., 2011).  
 This siRNA was also investigated in conjunction with both rosuvastatin and 
ezetimibe. The same type of mouse that was engineered to express higher levels of LDL-
cholesterol was used in this part of the study (Ason et al., 2011). The study took a similar 
structure, giving the mice either 10 mg/kg ezetimibe, 20 mg/kg of rosuvastatin, or both 
daily for 14 days; part of each group was also given 6 mg/kg of the lipidoid formula of 
SsiRNA at day 11 daily for the three remaining days (Ason et al., 2011). Effects on 
PCSK9 mRNA and serum PCSK9 were significant when the cholesterol drugs were 
administered: the ezetimibe alone and rosuvastatin alone each raised PCSK9 mRNA and 
serum PCSK9 2-fold, while the combination of the two drugs raised PCSK9 mRNA and 
serum PCSK9 4-fold (Ason et al., 2011). Administration of the PCSK9-inhibiting siRNA 
resulted in significant reductions in serum PCKS9 and non-HDL cholesterol as seen in 
	21 
Figure 6 below. Reductions in PCSK9 were also associated with increases in the 
numbers of LDL-receptors present on the hepatic cell membrane. 
 
 
Figure 6. Effects of PCSK9-inhibiting siRNA on serum PCSK9 when given in 
combination with ezetimibe and rosuvastatin. From Ason et al., 2011. 
 
As seen in Figure 6, siRNA was effective at reducing serum PCSK9 below control levels 
in conjunction with ezetimibe and rosuvastatin, and it had significant effects on the 
combination of ezetimibe and rosuvastatin despite the large increase in serum PCSK9 
caused by the combination (Ason et al., 2011). Additionally, the effects of the siRNA 
translated to reduced non-HDL cholesterol as seen in Figure 7 (Ason et al., 2011).  
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Figure 7. Effects of PCSK9-inhibiting siRNA on non-HDL cholesterol when given in 
combination with ezetimibe and rosuvastatin. From Ason et al., 2011. 
 
The siRNA proved as effect as rosuvastatin or ezetimibe in reducing non-HDL 
cholesterol as compared with the control, each lowering non-HDL cholesterol 
approximately 25% (Ason et al., 2011). Furthermore, the combination of ezetimibe and 
rosuvastatin with siRNA was incredibly successful at lowering non-HDL cholesterol, 
reaching an average reduction of 82% (Ason et al., 2011). This combination with the 
addition of siRNA was able to reduce non-HDL cholesterol 48% more than the 
combination alone (Ason et al., 2011). 
 This study also looked at the effects of these drugs on SREBP2 gene expression 
(Ason et al., 2011). The combination of ezetimibe and rosuvastatin had significant effects 
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on the expression of SREBP, resulting in a 11-fold increase over the control, possibly 
contributing the increase in serum PCSK9 that resulted from this therapy (Ason et al., 
2011). However, the siRNA, both in the control and when administered in conjunction 
with another drug, did not have any effect on the expression of SREBP2 (Ason et al., 
2011). 
 Antisense oligonucleotide inhibitors (ASOs) have also been used to inhibit 
PCSK9 gene expression. In a similar experiment to those conducted with siRNAs, the 
effects of the ASOs were tested in mice (Graham et al, 2007). A similar compound not 
complementary to any known DNA sequence was used as a control (Graham et al, 2007). 
Both the control and the ASO were administered twice weekly over the course of six 
weeks to mice fed high-fat Western diets (Graham et al, 2007). After six weeks, the ASO 
reduced PCSK9 mRNA 92% while increasing LDL-receptors on hepatic cells by 2-fold 
(Graham et al, 2007). The control animals remained unaffected (Graham et al, 2007). 
This resulted in significant reductions to serum cholesterol as seen in Table 4 (Graham et 
al, 2007).  
 
Table 4. Percent Reduction in Cholesterol in Mice Receiving ASOs 
 % Reduction in Cholesterol in treatment 
mice as compared with control mice 
Total Cholesterol 52% 
LDL-Cholesterol 32% 
HDL-Cholesterol 54% 
(Graham et al, 2007) 
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In addition to the expected effects on total cholesterol and LDL-cholesterol, mice 
receiving ASOs also had a significant reduction in HDL-cholesterol (Graham et al, 2007). 
This was also seen in a number of PCSK9-deficient mice and is thought to be the result 
of increase ApoE clearing proteins associated with increased LDL-receptor expression 
(Graham et al, 2007).  The ASOs were found to be very specific and selective, as they 
acted without affecting any other proteins in the mice (Graham et al, 2007).  
 
Monoclonal Antibodies against PCSK9 in Animal Models 
 Another popular strategy for reducing the effects PCSK9 apart from blocking 
gene expression directly is through the use of monoclonal antibodies to prevent PCSK9 
from binding the LDL receptor. The following two studies are both examples of the use 
of monoclonal antibodies against PCSK9 in animal models. 
 The first study used a monoclonal antibody against fully human PCSK9 in mice 
engineered to express human PCSK9 (Chan et al., 2009). The antibody was tested and 
found to have high affinity in binding for PCSK9 and was able to effectively block 
PCSK9 from binding to the LDL-receptor (Chan et al., 2009). The mice were given a 
single injection of 10 mg/kg of the monoclonal antibody or a control (Chan et al., 2009). 
Throughout the study, the monoclonal antibody outnumbered serum PCSK9 by 180-fold 
(Chan et al., 2009). Initially mice expressing high levels of PCSK9 had reduced LDL-
cholesterol uptake by the liver, but upon administration of the monoclonal antibody, this 
effect was reversed (Chan et al., 2009). The temporal response of circulating cholesterol 
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levels following administration of the 10 mg/kg monoclonal antibody are displayed in 
Table 5. 
 
Table 5. Percent reduction in cholesterol after administration of monoclonal 
antibody as compared with the control 
 24 Hours  72 hours 144 Hours 
Percent reduction 
in total cholesterol 
20% 26% 28% 
Percent reduction 
in HDL-
cholesterol 
-- 31% 24% 
(Chan et al., 2009).   
 
The reduction in HDL-cholesterol seen in Table 5 reflects that mice carry most of their 
circulating cholesterol in the form of HDL, so reductions in total cholesterol are likely to 
reduce the circulating HDL-cholesterol as well (Chan et al., 2009). LDL-receptor 
expression was 2.3 fold higher in the animals that received monoclonal antibodies as 
compared to the control (Chan et al., 2009). 
 This study also investigated the effect of increasing doses using two additional 
experiments. The first used doses of 3 mg/kg, 6 mg/kg, and 10 mg/kg and followed the 
animals over the course of the 12 following days (Chat et al., 2009). The response is 
shown below in Figure 8.  
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Figure 8. Effects of increasing doses of monoclonal antibody on total cholesterol 
over time. From Chan et al., 2009. 
 
After 9 days, only the doses of 6 or 10 mg/kg resulted in a decrease in total cholesterol 
that remained statistically significant, and after 12 days, none of the doses resulted in a 
statistically significant reduction in total cholesterol (Chan et al., 2009). 
In the second experiment, doses of either 10 or 30 mg/kg of the monoclonal 
antibody were given to mice engineered to express high levels of non-HDL-cholesterol, 
which closer mimics human distribution of cholesterol (Chan et al., 2009). The 10 mg/kg 
dose of monoclonal antibody resulted in a 44% decrease in non-HDL-cholesterol while 
the 30 mg/kg dose resulted in a 66% decrease in non-HDL cholesterol 24 hours after 
injection (Chan et al., 2009). After 48 hours, only those mice that received 30 mg/kg of 
monoclonal antibody still had statistically significant lowering of their non-HDL 
cholesterol at a 37% drop as compared with the control (Chan et al., 2009).  
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These monoclonal antibodies were also tested on mice with no LDL-receptors 
(Chan et al., 2009). These mice were unaffected by the monoclonal antibody, reaffirming 
that PCSK9 acts through the LDL-receptor (Chan et al., 2009).  
In a final experiment, the monoclonal antibodies were tested on cynomolgus 
monkeys to better approximate the response in humans (Chan et al., 2009). Monkeys 
offer an improvement over rodents as they carry a much higher percentage of their 
cholesterol in LDL as opposed to HDL, like mice (Chan et al., 2009). A single 3 mg/kg 
dose was administered to the monkeys (Chan et al., 2009). This resulted in a 48% 
reduction in total cholesterol after 10 days, with statistically significant decreases starting 
as early as 3 days (Chan et al., 2009). Furthermore, the LDL-cholesterol decreased 
significantly and rapidly, reaching statistical significance 8 hours after administration of 
the monoclonal antibody and reaching a low of 80% after 10 days (Chan et al., 2009). 
HDL-cholesterol was also transiently affected, reaching an 18% decrease as compared to 
baseline at day 3 (Chan et al., 2009). These effects were paralleled with a decrease in 
serum PCSK9; 15 minutes after administration of the monoclonal antibody, 97% of 
detectable PCSK9 had been removed from the blood (Chan et al., 2009). These levels 
were maintained for 3 days post-injection followed by a slow increase in circulating 
PCSK9 until it returned to baseline at day 14 (Chan et al., 2009).  
In a second study investigating the effect of monoclonal antibodies on PSCK9 
levels, a monoclonal antibody was generated containing fragment antigen-binding (Fab) 
with nanomolecular affinity to the LDL-binding portion of PCSK9 (Ni et al., 2011). The 
antibody was tested on mice that overexpress cholesteryl ester protein transferase and 
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heterozygous of the LDL-receptor in order to better mimic the cholesterol profile of 
humans (Ni et al., 2011). The mice received a single intravenous injection of the 
monoclonal antibody (Ni et al., 2011). LDL-cholesterol decreased up to 50% 48 hours 
after injection (Ni et al., 2011).  
The monoclonal antibody was also tested in rhesus monkeys (Ni et al., 2011). The 
monkeys were given a single intravenous injection of 3 mg/kg of body weight, which led 
to decreases in LDL-cholesterol up to 50% (Ni et al., 2011). The effect on LDL-
cholesterol was detected as early as 24 hours and maintained over the course of 2 weeks 
(Ni et al., 2011). The decrease in LDL-cholesterol was paralleled by a decrease in free 
circulating PCSK9, which dropped up to 70% with maximal reduction of LDL-
cholesterol (Ni et al., 2011). The half-life of the antibody was measured at 3.2 days or 77 
hours (Ni et al., 2011).  
 
Clinical Trials on Alirocumab 
 Alirocumab became the first PSCK9-inhibiting drug to gain FDA approval on 
July 24, 2015 (FDA, 2015). Alirocumab, known by the brand name, Praluent, is a 
monoclonal antibody to PSCK9 (FDA, 2015). While in clinical trials it was identified by 
the name EGN727/SAR236553, before being given the name alirocumab (Stein et al., 
2012).  
 Alirocumab has been tested in a number of clinical trials. In Phase I clinical trials, 
it was tested on individuals with both familial and non-familial hypercholesterolemia 
using both a single dose and a multi-dose system (Stein et al., 2012). Individuals in the 
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trial were health adults who were not taking any other cholesterol-lowering medication 
Those being tested on single dose were either given an intravenous injection or a 
subcutaneous injection with the drug (Stein et al., 2012). Those being tested on a single 
dose were either given an intravenous injection or a subcutaneous injection with the drug 
(Stein et al., 2012). Three fourths of the 40 subjects taking intravenous alirocumab were 
either given the drug while the remaining fourth were given a placebo (Stein et al., 2012). 
After every 8 subjects, safety was assessed before additional subjects were given the drug 
at escalating doses starting from 0.3 mg/kg of body weight to 12 mg/kg of body weight 
(Stein et al., 2012). The subcutaneous group included 32 subjects who followed the same 
basic study design and were assigned doses starting from 50 mg escalating to 250 mg 
(Stein et al., 2012).  
 Both the intravenous group and the subcutaneous group experienced dose-
dependent lowering of their LDL-cholesterol when compared with the placebo as shown 
in Tables 6 and 7 (Stein et al., 2012).  
 
Table 6. Reduction in LDL-cholesterol after single intravenous administration of 
alirocumab 
Dose 0.3 mg/kg 1 mg/kg 3 mg/kg 6 mg/kg 12 mg/kg 
% Decrease 
LDL-cholesterol 
as compared 
with placebo 
28.1% 42.2% 47.4% 56.5% 65.4% 
Day of peak 
LDL reduction 
Day 11 Day 11 Day 29 Day 22 Day 43 
(Stein et al., 2012) 
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Table 7. Reduction in LDL-cholesterol after single subcutaneous administration of 
alirocumab 
Dose 50 mg 100 mg 150 mg 250 mg 
%Decrease in 
LDL-
cholesterol as 
compared 
with placebo 
32.5% 39.9% 38.5% 45.7% 
Day of peak 
LDL 
reduction 
Day 15 Day 11 Day 15 Day 11 
(Stein et al., 2012) 
 
The intravenous dosing showed both increases in response as dose increased and 
increases in the longevity of the response (Stein et al., 2012). The subcutaneously dosing, 
however, also showed increased effectiveness with higher doses but the day of peak 
LDL-cholesterol reduction remained similar across doses (Stein et al., 2012).  
 The multidose aspect of the trial included a total of three subcutaneous doses 
(Stein et al., 2012). Subjects included 21 individuals with heterozygous familial 
hypercholesterolemia taking atorvastatin with LDL-cholesterol above 100 mg/dL, 30 
individuals with non-familial hypercholesterolemia also taking atorvastatin with LDL-
cholesterol above 100 mg/dL, and 10 subjects with non-familial hypercholesterolemia 
controlling their cholesterol through diet alone with LDL-cholesterol above 300 mg/dL 
(Stein et al., 2012). All subjects were adults 19-65 without diabetes or other known 
atherosclerotic disease (Stein et al., 2012). Subjects were randomly assigned either a 50 
mg, 100 mg, or 150 mg dose of alirocumab subcutaneously or a placebo on days 1, 29, 
and 43, which allowed for time for safety observation between doses (Stein et al., 2012). 
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The subjects were assessed both two weeks and four weeks after each dose (Stein et al., 
2012). Results showed significant reductions in LDL-cholesterol as shown in Table 8 
(Stein et al., 2012). 
 
Table 8. Reduction in LDL-cholesterol after 3 subcutaneous doses of Alirocumab 
Dose 50 mg 100 mg 150 mg 
% Reduction in LDL-cholesterol as 
compared with placebo 
39.2% 53.7% 61.0% 
(Stein et al., 2012) 
 
 Reductions to LDL-cholesterol shown in Table 8 correspond to similar reductions 
in serum PCSK9 (Stein et al., 2012). The effects were similar in all subjects regardless of 
whether or not their hypercholesterolemia was familial or whether or not their cholesterol 
was being managed with atorvastatin or diet (Stein et al., 2012). This suggests that the 
effects of alirocumab are additive with atorvastatin rather than synergistic (Stein et al., 
2012).  
 After a successful Phase I clinical trial, alirocumab was tested further in Phase II 
clinical trials. A double-blind, placebo-controlled clinical trial was conducted with adults 
age 18-75 with familial hypercholesterolemia (Roth et al., 2012). All subjects had LDL-
cholesterol levels above 100 mg/dL (Roth et al., 2012). All subjects were asked to start 
taking atorvastatin for at least 7 weeks prior to the study period and those not already 
taking atorvastatin were advised on compliance (Roth et al., 2012). A total of 92 subjects 
were randomized into one of three groups: one group took 80 mg atorvastatin plus 150 
mg alirocumab once every two weeks, the second group took 10 mg atorvastatin plus 150 
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mg alirocumab once every two weeks, and the last group took 80 mg atorvastatin plus a 
placebo every two weeks (Roth et al., 2012). The trial period lasted eight weeks for a 
total of four doses of alirocumab (Roth et al., 2012). After these eight weeks, subjects 
were allowed to return to their previous cholesterol-lowering therapy, whether it was via 
atorvastatin or some other treatment, for sixteen weeks of follow-up (Roth et al., 2012).  
 Randomization in this study was strong, resulting in similar demographic groups 
and risk of cardiovascular disease in each treatment group (Roth et al., 2012). 87% of 
subjects randomized completed all eight weeks of the study period (Roth et al., 2012).  
 After eight weeks of the study period, the group taking 80 mg atorvastatin plus 
alirocumab every two weeks had the greatest decrease at 73.2% below baseline (Roth et 
al., 2012).	The group taking alirocumab with 10 mg atorvastatin also had significantly 
lower LDL-cholesterol with a 66.2% reduction as compared to the group taking only 80 
mg atorvastatin, which had on average a 17.3% reduction in LDL-cholesterol (Roth et al., 
2012). While every subject in the groups taking alirocumab were successful in reducing 
LDL-cholesterol below 100 mg/dL, only 50% of those in the placebo group had LDL-
cholesterols below 100 mg/dL after eight weeks (Roth et al., 2012). Furthermore, 90% of 
those taking 80 mg atorvastatin plus alirocumab achieved a cholesterol level below 70 
mg/dL and 97% of those taking 10 mg atorvastatin plus alirocumab (Roth et al., 2012). In 
the placebo group, only 17% of subjects reduced cholesterol below 70 mg/dL, depiste 
taking 80 mg atorvastatin (Table 9) (Roth et al., 2012).  
 
Table 9. Effects of alirocumab and atorvastatin on LDL-cholesterol levels 
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 80 mg 
atorvastatin,  150 
mg alirocumab 
10 mg 
atorvastatin, 150 
mg alirocumab 
80 mg 
atorvastatin, 
placebo 
% reduction in 
LDL-cholesterol 
form baseline 
73.2% 66.2% 17.3% 
% of study group 
with cholesterol 
below 100 mg/dL 
after 8 weeks 
100% 100% 50% 
% of study group 
with cholesterol 
below 70 mg/dL 
after 8 weeks 
90% 97% 17% 
(Roth et al., 2012) 
 
Based on the results in Table 9, there was no significant difference between the groups 
taking 80 mg of atorvastatin or 10 mg atorvastatin in conjunction with alirocumab (Roth 
et al., 2012). This suggests that while atorvastatin up-regulates LDL-receptor activity, 
these effects plateau as dose increases (Roth et al., 2012). Real differences between study 
groups were due to the presence of alirocumab rather than the dose of atorvastatin, 
suggesting again that alirocumab has an additive effect on LDL-cholesterol as opposed to 
a synergistic one (Roth et al., 2012). 
While there was a clear decrease in LDL-cholesterol in the treatment groups 
taking alirocumab, these subjects also had higher detectable levels of PCSK9 in the blood 
as PCSK9 bound to antibodies took longer clearing from the blood (Roth et al., 2012). 
However, levels of free PCSK9 were reduced, paralleling the effect seen on LDL-
cholesterol (Roth et al., 2012).   
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In addition to alirocumab’s positive effects on LDL-cholesterol, it also 
successfully lowered total cholesterol and Lp(a) (Roth et al., 2012). Furthermore, the 
alirocumab seemed to have positive effects on HDL cholesterol (Roth et al., 2012). In the 
group taking 80 mg atorvastatin and 150 mg alirocumab, HDL-cholesterol increased 
5.8% whereas in the 80 mg atorvastatin and placebo group, it decreased 3.6%; however, 
these results were no statistically significant (p=0.06) (Roth et al., 2012). 
 Five subjects in the clinical trial were unable to continue due to adverse effects 
(Roth et al., 2012). Four of these five subjects were in the placebo group (Roth et al., 
2012). The fifth individual was in the 80 mg atorvastatin and 150 mg alirocumab group; 
this individual developed a rash and was taken off the medication (Roth et al., 2012). The 
rash responded well to anti-histamines, and the patient made a full recovery (Roth et al., 
2012). The distribution of adverse events suggests that alirocumab is safe to continue 
studying in further clinical trials (Roth et al., 2012).  
In the sixteen weeks of follow-up after the trial, individuals not taking any 
cholesterol-lowering medication had a slow return to baseline cholesterol levels, as 
expected (Roth et al., 2012) This suggests that the effects of alirocumab do not extend 
long-term after discontinuation of treatment (Roth et al., 2012).  
While results from the Phase II clinical trial were promising, a longer, Phase III 
clinical trial testing alirocumab with ezetimibe was key in helping the investigators fully 
understand the efficacy of this drug. The Phase III clinical trial was a 24-week, double-
blind randomized controlled trial using adults with a low risk of cardiovascular disease in 
the subsequent five years (Roth et al., 2014). This clinical trial was also the first clinical 
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trial to use an autoinjector for subcutaneous injections of alicrocumab (Roth et al., 2014). 
Subjects were asked not to take statins or other lipid-lowering medication in the four 
weeks leading up to the clinical trial (Roth et al., 2014). 100 subjects were randomized 
into one of two groups: a group taking 10 mg ezetimibe daily plus a placebo every two 
weeks and a group taking 10 mg ezetimibe daily plus 75 mg alirocumab every two weeks 
(Roth et al., 2014). Again, randomization resulted in a relatively even distribution of ages 
and risk of cardiovascular disease (Roth et al., 2014).  
At twelve weeks, individuals in the alirocumab arm that had LDL-cholesterol 
levels above 70 mg/dL during week eight were moved to a dose of 150 mg; this group 
ended up including 14 subjects (Roth et al., 2014). Results showed that those whose 
doses were increased at week 12 started with higher baseline levels of LDL-cholesterol as 
compared with the remaining subjects in the group, averaging 153.2 mg/dL as opposed to 
134.7 mg/dL (Roth et al., 2014). 
After the first twelve weeks, the alirocumab arm showed significant promise 
(Roth et al., 2014). The alirocumab group experienced an average drop of 53% from 
baseline as compared to a 20% drop from baseline in the ezetimibe group (Roth et al., 
2014). These results remained similar over the following twelve weeks (Figure 6) (Roth 
et al., 2014).  
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Figure 9. Change in LDL-Cholesterol over time on ezetimibe or alirocumab 
treatment. From Roth et al., 2014. 
 
Figure 9 shows significant drops in LDL-cholesterol over time in the alirocumab group 
(Roth et al. 2014). Within the alirocumab, 58% of the subjects reduced their LDL-
cholesterol by greater than 50% whereas only 3% of those in the ezetimibe only group 
achieved such significant reductions (Roth et al. 2014). In addition to changes in LDL-
cholesterol, the alirocumab group also showed moderate decreases in Lp(a) and 
triglycerides as well as moderate increases in HDL, although none of these changes were 
statistically significant (Roth et al. 2014).  
Nine adverse events occurred throughout the course of the clinical trial, five in the 
alirocumab group and four in the ezetimibe group (Roth et al. 2014). None of these 
events were thought to be related to the treatment (Roth et al. 2014). However, six 
patients in the alirocumab treatment-arm did develop antidrug-antibodies that persisted 
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throughout the follow-up period (Roth et al. 2014). Further analysis of the antibodies 
showed that they were non-neutralizing and had no effect on the pharmokinetics of the 
drug (Roth et al. 2014).  
Over the course of Phase I, II, and III clinical trials, alirocumab has shown itself 
to be both safe and effective as a LDL-cholesterol lowering medication for individuals 
with both familial and non-familial hypercholesterolemia. Furthermore, these trials 
suggest that it functions well in conjunction with ezetimibe or atorvastatin. 
 
Clinical trials on Evolocumab 
 Like alirocumab, evolocumab is a monoclonal antibody that gained FDA approval 
for individuals with familial hypercholesterolemia or individuals who need additional 
cholesterol-lowering medication on top of the benefits offered by statins (FDA, 2015). 
Evolocumab, also referred to by bland name Rapatha, gained approval in August of 2015, 
not long after alirocumab was approved (FDA, 2015).  
 Two Phase II clinical trials describe the effects of evolocumab, known at the time 
as AMG 145, on individuals taking statins and on statin-intolerant individuals. The first 
of these trials, conducted by Guigliano et al. used a multi-national, placebo-controlled 
randomized controlled trial ranging across seventy-eight countries (Guigliano et al., 
2012). 934 possible subjects, ages 18-80, were screened for eligibility; requirements 
included having an LDL-cholesterol of equal to or greater than 2 mmol/L or 77 mg/dL 
while on a stable dose of statins with or without additional ezetimibe and a history of 
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hypercholesterolemia (Guigliano et al., 2012). Individuals with serious comorbidities or 
individuals taking additional cholesterol-lowering medication were excluded (Guigliano 
et al., 2012). Of the 934 people screened, 631 were assigned to one of eight groups: 
evolocumab of either 70 mg, 105 mg, 140 mg, or placebo every two weeks, or 
evolocumab of the same three concentrations or placebo once every month (Guigliano et 
al., 2012). While subjects could not be blinded to their time schedules, masking was 
implemented within the two week and one month groups (Guigliano et al., 2012). The 
trial lasted a total of twelve weeks with a 95.6% follow-up rate (Guigliano et al., 2012).  
 All six groups taking evolocumab had significant reductions in LDL-cholesterol 
as compared with the placebo groups (Guigliano et al., 2012). The treatment groups on 
the two-week schedule had reductions in LDL-cholesterol between 41.8-66.1% whereas 
the treatment groups on the four-week schedule had reductions in LDL-cholesterol 
between 41.8-50.3% (Figure 10) (Guigliano et al., 2012).  
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Figure 10. Reductions in LDL-cholesterol with evolocumab over time. From 
Guigliano et al., 2012. 
 
As seen in Figure 10, the 140 mg evolocumab every two weeks group achieved the 
lowest LDL-cholesterol; of this group, 94% of the subjects had LDL-cholesterol levels 
below 1.8 mmol/L, approximately 70 mg/dL (Guigliano et al., 2012). Figure 10 also 
shows that individuals on the two-week schedule maintained a more consistent 
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cholesterol levels as compared to individuals on the four-week schedule (Guigliano et al., 
2012).  Furthermore, all evolocumab groups had significantly lower levels of total 
cholesterol, triglycerides, and serum PCSK9 when compared with the placebo (Guigliano 
et al., 2012).  
 Eight cardiovascular events occurred throughout the trial, evenly distributed 
across all groups (Guigliano et al., 2012). The trial did not offer enough statistical power 
to determine if these cardiovascular events were imbalanced towards any particular group 
(Guigliano et al., 2012). Additionally, 2% of patients developed injection-site reactions 
(Guigliano et al., 2012). Unlike alirocumab, no subjects developed antidrug-antibodies to 
evolocumab (Guigliano et al., 2012).  
 In the second Phase II clinical trial on evolocumab, Sullivan et al. tested the 
monoclonal antibody subcutaneously on statin-intolerant individuals through another 
multi-national, double-blind, placebo-controlled trial (Sullivan et al., 2012). Subjects 
were adults age 18-75 with hypercholesterolemia (Sullivan et al., 2012). All subjects fell 
into one of three categories: LDL-cholesterol above 100 mg/dL with coronary artery 
disease, LDL-cholesterol above 130 mg/dL with two or more risk factors for coronary 
artery disease, and LDL-cholesterol above 160 mg/dL with zero or one risk factors for 
coronary artery disease (Sullivan et al., 2012). 150 subjects were randomized into one of 
five groups: 280 mg evolocumab every 4 weeks, 350 mg evolocumab every 4 weeks, 420 
mg evolocumab every 4 weeks, 420 mg evolocumab every 4 weeks plus 10 mg ezetimibe 
daily, or placebo every 4 weeks plus 10 mg ezetimibe daily (Sullivan et al., 2012). The 
ezetimibe groups were not blinded to the presence of this drug (Sullivan et al., 2012). The 
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study period lasted a total of twelve weeks, and 94% of subjects received all of their 
doses (Sullivan et al., 2012).  
 Evolocumab showed a dose-depended reduction in LDL-cholesterol with the 
maximum effect two weeks after evolocumab administration and was maintained over 
the 12 weeks of the trial; the ezetimibe plus evolocumab group had the highest decreases 
in LDL-cholesterol of all the groups (Figure 11) (Sullivan et al., 2012). All reductions in 
the evolocumab-only group were statistically significant at a 41% reduction in the 280 
mg group, a 42% reduction in the 350 mg group, and a 51% reduction in the 420 mg 
group (Sullivan et al., 2012).  
 
 
Figure 11. Reductions in LDL-cholesterol over 12 weeks on evolocumab. From 
Sullivan et al., 2012. 
 
As shown in Figure 11 groups taking evolocumab only had a more significant decrease 
in LDL-cholesterol as compared to individuals taking the placebo plus ezetimibe 
(Sullivan et al., 2012). Furthermore, the evolocumab plus ezetimibe group had 
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significantly greater reductions in LDL-cholesterol at 51% reduction as compared with 
the placebo plus ezetimibe group at a 15% reduction (Sullivan et al., 2012).  
 Most subjects in the evolocumab plus ezetimibe group achieved LDL-cholesterol 
below the goal of 100 mg/dL or 70 mg/dL; however, the groups taking just ezetimibe had 
very few if any subjects reach these goals (Table 10) (Sullivan et al., 2012).   
 
Table 10. Percent of subjects achieving below 100 mg/dL or 70 mg/dL LDL-
cholesterol 
 % of subjects below 100 
mg/dL 
% of subjects below 70 
mg/dL 
Evolocumab only 54% 18% 
Evolocumab plus ezetimibe 90% 62% 
Ezetimibe only 7% 0% 
(Sullivan et al., 2012) 
 
The data from Table 10 shows the success of the combination of evolocumab and 
ezetimibe in reaching clinically significant levels of LDL-cholesterol (Sullivan et al., 
2012). For statin intolerant patients, ezetimibe was the best alternative therapy to statins 
on the market at the time of this clinical trial (Sullivan et al., 2012). The results offered 
by the combination of evolocumab and ezetimibe are similar to a high-dose statin 
(Sullivan et al., 2012).  
 In addition to the effects of evolocumab on LDL-cholesterol, evolocumab also 
resulted in a statically significant reduction in Lp(a), between 20-26% (Sullivan et al., 
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2012). The evolocumab plus ezetimibe group showed a small but statistically significant 
increase of 12% in HDL cholesterol (Sullivan et al., 2012).  The results also showed 
reductions in VLDL and triglycerides, although these measurements were not statistically 
significant (Sullivan et al., 2012).  
 Lastly, evolocumab appeared to be safe. Both groups reported equal numbers of 
adverse events and none were related to any of the treatment groups (Sullivan et al., 
2012).  
 These two studies paved the way for evolocumab to continue into Phase III 
clinical trials. Again, two separate trials were used: one investigated evolocumab with 
ezetimibe while the other focused on evolocumab in patients with heterozygous familial 
hypercholesterolemia.  
The first trial tested 615 subjects aged 18-80 with cholesterol levels between 100 
mg/dL and 190 mg/dL (Koren et al., 2014). Subjects were assigned one of six study 
groups: oral placebo daily and subcutaneous placebo injection biweekly, oral placebo 
daily and subcutaneous placebo injection monthly, 10 mg ezetimibe daily plus 
subcutaneous placebo injection biweekly, 10 mg ezetimibe daily plus subcutaneous 
placebo injection monthly, oral placebo daily plus 140 mg subcutaneous evolocumab 
biweekly, and oral placebo daily plus 420 mg subcutaneous evolocumab monthly (Koren 
et al., 2014). The last two groups had double the number of subjects as they were given 
the drug being investigated (Koren et al., 2014). The subjects were prohibited from using 
other lipid-lowering medication starting three months prior to the clinical trial (Koren et 
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al., 2014). Of 615 subjects, 97% of them completed the entire clinical trial (Koren et al., 
2014).  
In both the biweekly and monthly treatment, significant reductions in LDL-
cholesterol could be detected in the evolocumab groups (Koren et al., 2014). By the end 
of twelve weeks of follow-up, the biweekly evolocumab group had an average of a 57% 
decrease in LDL-cholesterol whereas the ezetimibe group had a 17.8% decrease and the 
placebo had a 0.1% decrease (Figure 12 part A) (Koren et al., 2014). Similarly potent 
results could be seen in the monthly group: the evolocumab group had a 56.1% decrease 
in LDL-cholesterol as compared with 18.5% from the ezetimibe group and 1.3% from the 
placebo group (Figure 12 part B) (Koren et al., 2014).  
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Figure 12. Changes in LDL-cholesterol over time with evolocumab and ezetimibe. 
Koren et al., 2014. 
 
As shown in Figure 12, evolocumab was characterized by a sharp decrease in LDL-
cholesterol following the first treatment (Koren et al., 2014). This reduced cholesterol 
was maintained in both the monthly and the biweekly groups over the course of the 
twelve weeks (Koren et al., 2014).   
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All subjects in the evolocumab groups experienced a decrease in the LDL-
cholesterol levels (Koren et al., 2014). However, in the ezetimibe groups, 92.9% of the 
biweekly and 91.3% of the monthly showed a decrease in LDL-cholesterol, suggesting 
that the drug was ineffective for some individuals (Koren et al., 2014). 69% of the 
evolocumab group had LDL-cholesterols below 70 mg/dL as compared with 1% in both 
the ezetimibe and placebo groups (Koren et al., 2014). In patients with metabolic 
syndrome, a biweekly administration of evolocumab was more effective than a monthly 
administration (Koren et al., 2014). Evolocumab also showed significant decreases in 
Ld(a), triglycerides, VLDL along with significant increases in HDL-cholesterol (Koren et 
al., 2014).  
While evolocumab was thought to be safe overall, two adverse events were 
thought to be related to the drug administration (Koren et al., 2014). One subject was 
found to have pancreatitis; this subject had a history of cholesystectomy and high alcohol 
consumption and was taking valproate semisodium concurrently with the monthly 
evolocuab (Koren et al., 2014). The second subject had transaminase and creatine kinase 
levels eight times higher than normal after being administered monthly evolocumab 
(Koren et al., 2014). After being taken off the drug, the subject’s enzymes returned to 
normal (Koren et al., 2014). Despite these adverse events, the overall incidence of 
adverse events was equal across treatment groups and no other events were connected 
with evolocumab administration (Koren et al., 2014). Furthermore, no antidrug-
antibodies were found in any of the subjects (Koren et al., 2014).  
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The second Phase III clinical trial looked at the effects of evolocumab on patients 
with heterozygous familial hypercholesterolemia through a double-blind, placebo-
controlled randomized controlled trial (Raal et al., 2014).  Subjects were aged 18-80 and 
were all taking statins for at least four weeks prior to the start of the study (Raal et al., 
2014). 331 subjects were chosen for the trial and were randomized into four groups: 
subcutaneous placebo injection every two weeks, subcutaneous placebo injection every 
month, 140 mg subcutaneous evolocumab injection every two weeks, 420 mg 
subcutaneous evolocumab injection every month (Raal et al., 2014). The last two 
treatment groups had twice the subjects (Raal et al., 2014). All injections were done using 
an autoinjection pen (Raal et al., 2014). Randomization was stratified by cholesterol 
levels and ezetimibe group in order to create comparable study groups (Raal et al., 2014).  
Of the 331 subjects, 325 completed the entire twelve weeks of the study (Raal et 
al., 2014). Compared with the placebo groups, the biweekly evolocumab group had an 
average decrease of 59.2% at week twelve; the monthly group had similar results with an 
average decrease of 61.3% at week twelve when compared with the placebo group (Raal 
et al., 2014). Reductions after the first two weeks of the clinical trial remained relatively 
consistent within the evolocumab group over the course of the remaining ten weeks of the 
trial (Raal et al., 2014). Additionally, both evolocumab groups had significant reductions 
in Lp(a) and triglycerides as compared with the placebo group (Raal et al., 2014). 
However, the biweekly evolocumab group did show a more favorable decrease in 
triglycerides than the monthly evolocumab group (Raal et al., 2014).   
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Evolocumab was again shown to be relatively safe (Raal et al., 2014). However, a 
few differences in incidences of adverse events were found when comparing treatment 
and placebo groups (Raal et al., 2014). For example, the evolocumab group had higher 
rates of nasopharyngitis at 9% when compared with the placebo group at 5%; 
additionally, 5% of the treatment group experienced muscle-related adverse events as 
compared with 1% of the placebo group (Raal et al., 2014).  
Overall, in both Phase II and Phase III clinical trials, evolocumab offers promise 
in its efficacy and safety. It showed significant decreases in LDL-cholesterol in treatment 
of statin-intolerant patients, patients with familial hypercholesterolemia, and other 
patients with high cholesterol, in conjunction with both statins and ezetimibe.  
 
Administration of siRNA PCSK9 inhibitors in humans 
 While the use of siRNA to inhibit PCSK9 gene expression proved successful in 
animal models, limited research has been conducted on siRNA PCSK9 inhibitors in 
humans. A single-blind, placebo-controlled Phase I clinical trial was the first of its kind 
investigating this method of PCSK9 inhibition (Fitzgerald et al., 2014).  
 This clinical trial tested healthy adults, ages 18-65, with LDL-cholesterol levels 
higher than 3 mmol/L, approximately 116 mg/dL (Fitzgerald et al., 2014). Three of every 
four participants were placed in the treatment group, which was given an intravenous 
injection of siRNA in a lipid nanoparticle similar to those investigated in animal studies; 
the placebo group was simply given intravenous saline (Fitzgerald et al., 2014). A total of 
8 volunteers were placed in the placebo group while 24 were placed in the treatment 
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group (Fitzgerald et al., 2014). All participants received oral corticosteroids, histamine 
receptor blockers, and paracetamol to prevent an infusion reaction at the injection site 
(Fitzgerald et al., 2014). Then, subjects received either a single, one-hour infusion of the 
placebo or 0.015, 0.045, 0.090, 0.150. 0.250, or 0.400 mg/kg of siRNA lipid nanoparticle 
(Fitzgerald et al., 2014). Initially, only three subjects were assigned to each group, but 
after the 0.250 and 0.400 groups were deemed to be safe, an additional three subjects was 
assigned to each of these groups (Fitzgerald et al., 2014). Follow-up visits occurred over 
the course of the subsequent 180 days (Fitzgerald et al., 2014).  
 Safety was one of the primary endpoints assessed during this clinical trial. No 
adverse events were linked to treatment with the siRNA (Fitzgerald et al., 2014). One 
individual in a low-dose group had a deep vein thrombosis, but the investigators 
determined this was likely unrelated to the treatment as lipid-nanoparticles carrying 
neutral substances have been given at higher doses in other studies, and no deep vein 
thrombosis had been noted (Fitzgerald et al., 2014). A number of subjects in both 
treatment and placebo group had rashes, but they were evenly distributed across both 
treatment and doses that the rashes were not thought to be related to the treatment 
(Fitzgerald et al., 2014). No significant changes to liver function or enzyme levels were 
discovered after administration of the siRNA (Fitzgerald et al., 2014).  
 The pharmacokinetics of the drug suggest rapid distribution of siRNA in the 
plasma with the peak concentrations of the drug occurring directly after infusion 
(Fitzgerald et al., 2014). Reductions in serum PCSK9 appeared to be dose-dependent and 
lasted longer with increasing doses (Fitzgerald et al., 2014). The highest dose achieved a 
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70% drop in serum PCSK9 levels as compared with the placebo (Fitzgerald et al., 2014). 
In the placebo group, a slight increase in PCSK9 was seen over the first two days; this 
was thought to be related to the premedication to prevent infusion reactions (Fitzgerald et 
al., 2014). However, because the effects of the siRNA treatment lasted a total of seven 
days, after the premedication had worn off, the effects seen in the treatment groups are 
thought to be independent of the premedication (Fitzgerald et al., 2014).  
 To measure the specificity of the siRNA, the investigators chose to measure the 
gene expression of transthyretin, a protein that can normally be found in the plasma 
(Fitzgerald et al., 2014). Expression of transthyretin is independent of PCSK9 and was 
not expected to change with changes in PCSK9 silencing (Fitzgerald et al., 2014). Levels 
of serum transthyretin remained constant even after a 0.400 mg/kg dose of the siRNA, 
suggesting that gene silencing as specific to PCSK9 and did not interfere with other 
proteins (Fitzgerald et al., 2014).  
 Reductions in serum PCSK9 after the infusion of the siRNA was paralleled by a 
rapid decrease in LDL-cholesterol (Fitzgerald et al., 2014). The highest dose of the 
siRNA resulted in an average decrease in LDL-cholesterol of 40% with the highest 
reduction of 70% in one individual (Fitzgerald et al., 2014). The change in LDL-
cholesterol over time in the highest dose group and the average minimum cholesterol per 
treatment group can be seen in Figure 13. 
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Figure 13. Effects of PCSK9 inhibiting siRNA on LDL-cholesterol. Fitzgerald et al., 
2014. 
 
 
The effects of the siRNA occurred quickly with the first statistically significant evidence 
of LDL-cholesterol reduction occurring at day 2, with a peak reduction in LDL-
cholesterol occurring at day 4 (Fitzgerald et al., 2014). Overall, administration of PCSK9 
inhibitors through siRNA appears to be safe and effective in lowering LDL-cholesterol, 
particularly at the higher doses.  
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DISCUSSION 
 
 Investigation of PCSK9 inhibitors as a treatment for lowering LDL-cholesterol 
has shown promise in animal studies and clinical trials. In animal studies three different 
methods of lowering cholesterol have been successful: siRNA, ASOs, and monoclonal 
antibodies (Frank-Kamenetsky et al., 2008; Graham et al, 2007; Chan et al., 2009; Ni et 
al., 2011). The effects of these therapies were both effective and rapid. When siRNA was 
used to inhibit PCSK9 expression, significant reductions in LDL-cholesterol were noted 
even when the drug was only given for three days (Anson et al., 2011). In studies using 
monoclonal antibodies against PCSK9, significant reductions in PCSK9 were noted just 
twenty hours after administration of the antibodies (Chan et al., 2009).  
 While animal studies showed decreases in HDL-cholesterol accompanying 
decreases in LDL-cholesterol, these effects did not carry over to human studies; this is 
thought to be a result of the differences in cholesterol content in rodents and humans 
(Chan et al., 2009; Graham et al., 2007). In fact in humans modest increases in HDL-
cholesterol were seen with inhibition of PCSK9 (Sullivan et al., 2012).   
 While statins result in a feedback response on SREBP2 reducing the efficacy of 
this class of drug, this effect does not occur with PCSK9 inhibitors. Statins have a less 
potent effect than expected at high doses due to the feedback on SREBP, which up-
regulates PCSK9, causing the effects of this drug to plateau as dose increase (Tibolla et 
al., 2011). However, when siRNA was used in animal studies to block expression of 
PCSK9, no feedback response was noted on SREBP expression, which makes the PCSK9 
gene a particularly attractive target (Anson et al., 2011).  
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 Studies of monoclonal antibodies against PCSK9 in humans have also shown that 
this class of drugs is effective. Monoclonal antibody PCSK9 inhibitors were shown to be 
functional for individuals with statin intolerance, familial hypercholesterolemia, or 
simply with high cholesterol (Roth et al., 2012; Sullivan et al., 2012; Koren et al., 2014). 
While early laboratory experiments on PCSK9 suggested that PCSK9 inhibitors might 
have a synergistic effect when administered alongside statins, data from the alirocumab 
clinical trials strongly suggests an additive benefit as opposed to simply a synergistic one 
when taking PCSK9 inhibitors alongside statins (Tibolla et al., 2011; Stein et al., 2012).  
 Data from clinical trials shows that both alirocumab and evolocumab are 
extremely effective in lowering LDL-cholesterol below 100 mg/dL (Roth et al., 2012; 
Sullivan et al., 2012). These effects were seen when alirocumab or evolocumab were 
administered in addition to statins or as an alternative to ezetimibe (Roth et al., 2012; 
Sullivan et al., 2012). Furthermore, these differences remained true when quantifying the 
number of individuals who successfully lowered their LDL-cholesterol to 70 mg/dL or 
below, which is recommended for individuals with a high risk of cardiovascular disease 
(Roth et al., 2012; Sullivan et al., 2012; “Familial Hypercholesterolemia Treatment & 
Management,” 2015). These differences in achieving target LDL-cholesterol were 
particularly evident when comparing individuals taking evolocumab with those taking 
ezetimibe, which is one of the few medications previously available to 
hypercholesterolemic patients with statin intolerance (Sullivan et al., 2012; Vandenberg 
& Robinson, 2010).  
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 In addition to the effects on LDL-cholesterol and total cholesterol, evolocumab 
and alirocumab had favorable effects on other targets such as triglycerides, VLDL, and 
Lp(a). Several studies showed statically significant reductions in triglycerides (Guigliano 
et al., 2012, Koren et al., 2014, Raal et al., 2014). These reductions were more significant 
in evolocumab studies when the drug was administered on a biweekly schedule as 
opposed to a monthly schedule (Raal et al., 2014). One study also found statically 
significant reductions in VLDL (Koren et al., 2014). Finally, both alirocumab and 
evolocumab showed statistically significant reductions in Lp(a) (Roth et al., 2012; 
Sullivan et al., 2012; Raal et al., 2014). In one study, these reductions were higher than 
20% (Sullivan et al., 2012). Lp(a) is important as it is thought to have a causal 
relationship with cardiovascular disease, but remains unaffected by statin therapy (Tada 
et al., 2013). This is of particular relevance to patients with familial hypercholesterolemia 
who have high levels of Lp(a) (Tada et al., 2013). Further investigation of PCSK9’s 
effects on triglycerides, VLDL, and Lp(a) could clarify its mechanism of action and bring 
to light therapies involving PCSK9 inhibitors for other forms of dyslipidemia. 
 Clinical trials investigating evolocumab tended to use one of two different time 
schedules: biweekly or monthly administration (Guigliano et al., 2012; Koren et al., 
2014; Raal et al., 2014). While both time courses appeared to have a strong effect on 
LDL-cholesterol, biweekly evolocumab resulted in more consistent LDL-cholesterol 
levels over time (Guigliano et al., 2012). Furthermore, in patients with metabolic 
syndrome, the biweekly schedule proved to be more effective in lowering LDL-
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cholesterol even though the total dose of evolocumab over the course of the month was 
lower (Koren et al., 2014).  
 Both evolocumab and alirocumab appeared to be safe throughout clinical trials; 
the incidence of adverse events remained generally similar across treatment groups and 
doses (Roth et al., 2012; Guigliano et al., 2012; Sullivan et al., 2012). Two categories of 
adverse events appeared to have higher incidence among individuals using evolocumab 
as compared with placebo groups: nasophyngitis and muscle-related adverse events; 
however these events only occurred among a small percentage of subjects and were not 
life-threatening (Raal et al., 2014). While cardiovascular events were recorded in clinical 
trials, statistical power was not necessarily large enough to make firm conclusions that 
the precipitation of cardiovascular events was unrelated to the treatment (Guigliano et al., 
2012). It is important to note that most studies exclude very high-risk patients with 
hypercholestolemia; for these reasons, safety should continue to be assessed as 
monoclonal antibodies are investigated further.  
 Since these monoclonal antibodies against PCSK9 have been approved for use, 
investigation of siRNA inhibiting PCSK9 gene expression has begun in humans 
(Fitzgerald et al., 2014). This is a particularly exciting as it bridges advancements in gene 
regulation and this new method of reducing cholesterol. Furthermore, it offers additional 
insights into the function of siRNA and PCSK9.	While clinical trials using siRNA are 
still in the early phases, this strategy of regulating PCSK9 holds promise based on the 
success seen so far (Fitzgerald et al., 2014). Investigation of siRNAs should continue to 
be studied for both efficacy and safety.  
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 In conclusion, the PCSK9 inhibitors are an excellent addition to cholesterol-
lowering medications. The approval of alirocumab and evolocumab offer patients with 
statin intolerance a significant improvement over therapies previously available. 
Furthermore, individuals with very high cholesterol can now use PCSK9 inhibitors in 
addition to statins to safely lower their cholesterol to recommended levels. With 
continuing development of this class of drugs, both in the form of monoclonal antibodies 
and siRNA, we can anticipate further progress in creating safe and effective treatment 
options for individuals with hypercholesterolemia.	  
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